The role of BAFF in the progression of rheumatoid arthritis

Cytokine

Volumn 76, Issue 2, 2015, Pages 537-544

  Wei, Fang ^a,b   Chang, Yan ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

B cell activating factor; BAFF R; BCMA; Immune cells; Rheumatoid arthritis; TACI

Indexed keywords

ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; BLISIBIMOD; BRIOBACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; TABALUMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TNFRSF13C PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

B LYMPHOCYTE; CELL INTERACTION; DENDRITIC CELL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ARTHRITIS, RHEUMATOID; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; DISEASE PROGRESSION; HUMANS;

EID: 84943815876     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.07.014     Document Type: Review

References (105)

1. Genovese M.C., Fleischmann R.M., Greenwald M., Satterwhite J., Veenhuizen M., Xie L., Berclaz P.Y., Myers S., Benichou O. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann. Rheum. Dis. 2013, 72(9):1461-1468.
2. Feldmann M., Brennan F.M., Maini R.N. Rheum arthritis. Cell 1996, 85(3):307-310.
3. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937):356-361.
4. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376(9746):1094-1108.
5. Richez C., Truchetet M.E., Schaeverbeke T., Bannwarth B. Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs 2014, 23(9):1285-1294.
6. Pillai S., Mattoo H., Cariappa A. B cells and autoimmunity. Curr. Opin. Immunol. 2011, 23(6):721-731.
7. Liu Z., Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011, 32(8):388-394.
8. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 2006, 18(5):284-289.
9. Hengeveld P.J., Kersten M.J. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J. 2015, 5:e282.
10. Tangye S.G., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 2006, 18(5):305-317.
11. Striz I., Brabcova E., Kolesar L., Sekerkova A. Cytokine networking of innate immunity cells: a potential target of therapy. Clin. Sci. (Lond.) 2014, 126(9):593-612.
12. Schneider P., Tschopp J. BAFF and the regulation of B cell survival. Immunol. Lett. 2003, 88(1):57-62.
13. Liu Z., Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp. Cell Res. 2011, 317(9):1270-1277.
14. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., Kipps T.J. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J. Immunol. 2005, 174(2):864-870.
15. Lee G.H., Lee J., Lee J.W., Choi W.S., Moon E.Y. B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-alpha. Int. Immunopharmacol. 2013, 17(1):142-147.
16. Mackay F., Mackay C.R. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol. 2002, 23(3):113-115.
17. Moisini I., Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin. Exp. Immunol. 2009, 158(2):155-163.
18. Pelekanou V., Notas G., Kampa M., Tsentelierou E., Stathopoulos E.N., Tsapis A., Castanas E. BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis. PLoS One 2013, 8(12):e83250.
19. Woodland R.T., Schmidt M.R., Thompson C.B. BLyS and B cell homeostasis. Semin. Immunol. 2006, 18(5):318-326.
20. Tan S.M., Xu D., Roschke V., Perry J.W., Arkfeld D.G., Ehresmann G.R., Migone T.S., Hilbert D.M., Stohl W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003, 48(4):982-992.
21. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190(11):1697-1710.
22. Bossen C., Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 2006, 18(5):263-275.
23. Gross J.A., Dillon S.R., Mudri S., Johnston J., Littau A., Roque R., Rixon M., Schou O., Foley K.P., Haugen H., McMillen S., Waggie K., Schreckhise R.W., Shoemaker K., Vu T., Moore M., Grossman A., Clegg C.H. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15(2):289-302.
24. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., Frew E., Scott M.L. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293(5537):2111-2114.
25. Goenka R., Matthews A.H., Zhang B., O'Neill P.J., Scholz J.L., Migone T.S., Leonard W.J., Stohl W., Hershberg U., Cancro M.P. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J. Exp. Med. 2014, 211(1):45-56.
26. Carter R.H. A role for BLyS in tissue inflammation?. Arthritis Rheum. 2003, 48(4):882-885.
27. Balázs M., Martin F., Zhou T., Kearney J. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002, 17(3):341-352.
28. Huard B., Schneider P., Mauri D., Tschopp J., French L.E. T cell costimulation by the TNF ligand BAFF. J. Immunol. 2001, 167(11):6225-6231.
29. Sutherland A.P., Ng L.G., Fletcher C.A., Shum B., Newton R.A., Grey S.T., Rolph M.S., Mackay F., Mackay C.R. BAFF augments certain Th1-associated inflammatory responses. J. Immunol. 2005, 174(9):5537-5544.
30. Zekavat G., Rostami S.Y., Badkerhanian A., Parsons R.F., Koeberlein B., Yu M., Ward C.D., Migone T.S., Yu L., Eisenbarth G.S., Cancro M.P., Naji A., Noorchashm H. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol. 2008, 181(11):8133-8144.
31. Lam Q.Lai Kwan, Ko O.King Hung, Zheng B.J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. USA 2008, 105(39):14993-14998.
32. Qin Q., Chang Y., Wang D., Wu Y., Zhang L.L., Wei W. TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis. Int. Immunopharmacol. 2011, 11(12):2167-2175.
33. Chang Y., Wu Y., Wang D., Wei W., Qin Q., Xie G., et al. Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. Rheumatology (Oxford) 2011, 50(5):862-870.
34. Fu L., Lin-Lee Y.C., Pham L.V., Tamayo A.T., Yoshimura L.C., Ford R.J. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 2009, 113(19):4627-4636.
35. Pieper K., Grimbacher B., Eibel H. B-cell biology and development. J. Allergy Clin. Immunol. 2013, 131(4):959-971.
36. Jin X., Ding C. Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis. Expert Opin. Biol. Ther. 2013, 13(2):315-322.
37. Barbosa R.R., Silva S.L., Silva S.P., Melo A.C., Pereira-Santos M.C., Barata J.T., Hammarström L., Cascalho M., Sousa A.E. Reduced BAFF-R and increased TACI expression in common variable immunodeficiency. J. Clin. Immunol. 2014, 34(5):573-583.
38. Yan M., Wang H., Chan B., Roose-Girma M., Erickson S., Baker T., Tumas D., Grewal I.S., Dixit V.M. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2001, 2(7):638-643.
39. Kanswal S., Katsenelson N., Selvapandiyan A., Bram R.J., Akkoyunlu M. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J. Immunol. 2008, 181(2):976-990.
40. Park M.A., Li J.T., Hagan J.B., Maddox D.E., Abraham R.S. Common variable immunodeficiency: a new look at an old disease. Lancet 2008, 372(9637):489-502.
41. Mackay F., Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008, 19(3-4):263-276.
42. Tsuji S., Cortesao C., Bram R.J., Platt J.L., Cascalho M. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood 2011, 118(22):5832-5839.
43. Coquery C.M., Erickson L.D. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit. Rev. Immunol. 2012, 32(4):287-305.
44. O'Connor B.P., Raman V.S., Erickson L.D., Cook W.J., Weaver L.K., Ahonen C., Lin L.L., Mantchev G.T., Bram R.J., Noelle R.J. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 2004, 199(1):91-98.
45. Coquery C.M., Loo W.M., Wade N.S., Bederman A.G., Tung K.S., Lewis J.E., Hess H., Erickson L.D. BAFF regulates T follicular helper cells and affects accumulation and IFNgamma production in autoimmunity. Arthritis Rheumatol. 2014, 67(3):773-784.
46. + T cell and B cell responses in lupus-prone mice. PLoS One 2014, 9(7):e102284.
47. Scheinman R. NF-κB and rheumatoid arthritis: will understanding genetic risk lead to a therapeutic reward?. For. Immunopathol. Dis. Ther. 2013, 4(2):93-110.
48. Li P.P., Liu D.D., Liu Y.J., Song S.S., Wang Q.T., Chang Y., Wu Y.J., Chen J.Y., Zhao W.D., Zhang L.L., Wei W. BAFF/BAFF-R involved in antibodies production of rats with collagen-induced arthritis via PI3K-Akt-mTOR signaling and the regulation of paeoniflorin. J. Ethnopharmacol. 2012, 141(1):290-300.
49. Hu J., Yu Y., Han H., Civoli F., Zhuang Y., Thomas J., Swanson S., Jing S., Gupta S. Development of a novel BAFF responsive cell line suitable for detecting bioactive BAFF and neutralizing antibodies against BAFF-pathway inhibiting therapeutics. Cells 2014, 3(1):79-91.
50. Henley T., Kovesdi D., Turner M. B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur. J. Immunol. 2008, 38(12):3543-3548.
51. So T., Croft M. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front. Immunol. 2013, 4:139.
52. Xu L.G., Shu H.B. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-κB activation and IL-10 production. J. Immunol. 2002, 169(12):6883-6889.
53. Lin W.W., Hildebrand J.M., Bishop G.A. A complex relationship between TRAF3 and non-canonical NF-kappaB2 activation in B lymphocytes. Front. Immunol. 2013, 4:477.
54. Rickert R.C., Jellusova J., Miletic A.V. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 2011, 244(1):115-133.
55. Liao G., Zhang M., Harhaj E.W., Sun S.C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 2004, 279(25):26243-26250.
56. Gardam S., Sierro F., Basten A., Mackay F., Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008, 28(3):391-401.
57. Hildebrand J.M., Luo Z., Manske M.K., Price-Troska T., Ziesmer S.C., Lin W., Hostager B.S., Slager S.L., Witzig T.E., Ansell S.M., Cerhan J.R., Bishop G.A., Novak A.J. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J. Exp. Med. 2010, 207(12):2569-2579.
58. Morrison M.D., Reiley W., Zhang M., Sun S.C. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the non canonical NF-kappaB signaling pathway. J. Biol. Chem. 2005, 280(11):10018-10024.
59. Hatzoglou A., Roussel J., Bourgeade M.F., Rogier E., Madry C., Inoue J., Devergne O., Tsapis A. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF)1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 2000, 165(3):1322-1330.
60. Marsters S.A., Yan M., Pitti R.M., Haas P.E., Dixit V.M., Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. 2000, 10(13):785-788.
61. Shu H.B., Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc. Natl. Acad. Sci. USA 2000, 97(16):9156-9161.
62. Xia X.Z., Treanor J., Senaldi G., Khare S.D., Boone T., Kelley M., Theill L.E., Colombero A., Solovyev I., Lee F., McCabe S., Elliott R., Miner K., Hawkins N., Guo J., Stolina M., Yu G., Wang J., Delaney J., Meng S.Y., Boyle W.J., Hsu H. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J. Exp. Med. 2000, 192(1):137-143.
63. Bosello S., Youinou P., Daridon C., Tolusso B., Bendaoud B., Pietrapertosa D., Morelli A., Ferraccioli G. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J. Rheumatol. 2008, 35(7):1256-1264.
64. Thorn M., Lewis R.H., Mumbey-Wafula A., Kantrowitz S., Spatz L.A. BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion. Cell. Immunol. 2010, 261(1):9-22.
65. Marston B., Looney R.J. Translating the effects of BAFF in SLE. Nat. Rev. Rheumatol. 2010, 6(9):503-504.
66. Stohl W., Jacob N., Guo S., Morel L. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010, 62(8):2432-2442.
67. Geng Y., Zhang Z.L. Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients. Int. J. Rheum. Dis. 2012, 15(5):478-485.
68. Weyand C.M. Immunopathologic aspects of rheumatoid arthritis: who is the conductor and who plays the immunologic instrument?. J. Rheumatol. Suppl. 2007, 79:9-14.
69. Greenwald M., Szczepanski L., Kennedy A., Veenhuizen M., Komocsar W.J., Polasek E., Guerrettaz K., Berclaz P.Y., Lee C. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Res. Ther. 2014, 16(4):415-425.
70. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N.Y. Acad. Sci. 2005, 1050:34-39.
71. Ma N., Xiao H., Marrero B., Xing C., Wang X., Zheng M., Han G., Chen G., Hou C., Shen B., Li Y., Wang R., Jiang Z. Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells. Cell. Immunol. 2014, 289(1-2):140-144.
72. Moura R.A., Cascao R., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 2011, 50(2):278-282.
73. Moura R.A., Canhao H., Polido-Pereira J., Rodrigues A.M., Navalho M., Mourao A.F., et al. BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis. J. Rheumatol. 2013, 40(8):1293-1302.
74. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., et al. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 2005, 115(11):3083-3092.
75. Nagatani K., Itoh K., Nakajima K., Kuroki H., Katsuragawa Y., Mochizuki M., et al. Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum. 2007, 56(11):3554-3563.
76. Chang Y., Jia X., Sun X., Xu S., Wu Y., Zhang L., et al. APRIL promotes proliferation, secretion and invasion of fibroblast-like synoviocyte from rats with adjuvant induced arthritis. Mol. Immunol. 2015, 64(1):90-98.
77. Cheema G.S.R.V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44(6):1313-1319.
78. Assi L.K., Wong S.H., Ludwig A., Raza K., Gordon C., Salmon M., et al. Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 2007, 56(6):1776-1786.
79. Scapini P.C.A., Nardelli B., Calzetti F., Roschke V., Merigo F., Tamassia N., Pieropan S., Biasi D., Sbarbati A., Sozzani S., Bambara L., Cassatella M.A. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005, 105(2):830-837.
80. Jeon S.T., Kim W.J., Lee S.M., Lee M.Y., Park S.B., Lee S.H., Kim I.S., Suk K., Choi B.K., Choi E.M., Kwon B.S., Lee W.H. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol. Cell Biol. 2010, 88(2):148-156.
81. Zhang M., Ko K.H., Lam Q.L., Lo C.K., Srivastava G., Zheng B., et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int. Immunol. 2005, 17(8):1081-1092.
82. Kalled S.L. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 2005, 204:43-54.
83. Zheng Y., Gallucci S., Gaughan J.P., Gross J.A., Monestier M. A role for B cell-activating factor of the TNF family in chemically induced autoimmunity. J. Immunol. 2005, 175(9):6163-6168.
84. Chang S.K., Mihalcik S.A., Jelinek D.F. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J. Immunol. 2008, 180(11):7394-7403.
85. Chang Y., Sun X., Jia X., Xu S., Wei F., Yang X., et al. Expression and effects of B-lymphocyte stimulator and its receptors in T cell-mediated autoimmune arthritis. Int. Immunopharmacol. 2015, 24(2):451-457.
86. Nakajima K., Itoh K., Nagatani K., Okawa-Takatsuji M., Fujii T., Kuroki H., et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand. J. Rheumatol. 2007, 36(5):365-372.
87. Reyes L.I., Leon F., Gonzalez P., Rozas M.F., Labarca C., Segovia A., et al. Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 2008, 42(2):170-178.
88. Burger J.A., Zvaifler N.J., Tsukada N., Firestein G.S., Kipps T.J. Fibroblast-like synoviocytes support B-cell pseudo emperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J. Clin. Invest. 2001, 107(3):305-315.
89. Wang Q., Ma Y., Liu D., Zhang L., Wei W. The roles of B cells and their interactions with fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Int. Arch. Allergy Immunol. 2011, 155(3):205-211.
90. Rochas C., Hillion S., Saraux A., Mageed R.A., Youinou P., Jamin C., Devauchelle V. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. Arthritis Rheum. 2009, 60(5):1261-1271.
91. Selmi C., Generali E., Massarotti M., Bianchi G., Scire C.A. New treatments for inflammatory rheumatic disease. Immunol. Res. 2014, 60(2-3):277-288.
92. Stohl W., Merrill J.T., McKay J.D., Lisse J.R., Zhong Z.J., Freimuth W.W., et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J. Rheumatol. 2013, 40(5):579-589.
93. Greenwald M., Szczepanski L., Kennedy A., Veenhuizen M., Komocsar W.J., Polasek E., Guerrettaz K., Berclaz P.Y., Lee C. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Res. Ther. 2014, 16(4):415-434.
94. Kamal A., Khamashta M. The efficacy of novel B cell biologics as the future of SLE treatment: a review. Autoimmun. Rev. 2014, 13(11):1094-1101.
95. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003, 48(11):3253-3265.
96. Blüml S., McKeever K., Ettinger R., Smolen J., Herbst R. B-cell targeted therapeutics in clinical development. Arthritis Res. Ther. 2013, 15(Suppl. 1):S4.
97. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008, 58(1):61-72.
98. Genovese M.C., Kinnman N., de La Bourdonnaye G., Pena Rossi C., Tak P.P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011, 63(7):1793-1803.
99. van Vollenhoven R.F., Kinnman N., Vincent E., Wax S., Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011, 63(7):1782-1792.
100. Nanda S. Therapy: atacicept lacks clinical efficacy in RA. Nat. Rev. Rheumatol. 2011, 7(6):313.
101. Bracewell C., Isaacs J.D., Emery P., Ng W.F. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 2009, 9(7):909-919.
102. Genovese M.C., Lee E., Satterwhite J., Veenhuizen M., Disch D., Berclaz P.Y., et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2013, 72(9):1453-1460.
103. Smolen J.S., Weinblatt M.E., van der Heijde D., Rigby W.F., van Vollenhoven R., Bingham C.O., et al. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann. Rheum. Dis. 2015.
104. Hsu H., Khare S.D., Lee F., Miner K., Hu Y.L., Stolina M., Hawkins N., Chen Q., Ho S.Y., Min H., Xiong F., Boone T., Zack D.J. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models autoimmune disease. Clin. Exp. Rheumatol. 2012, 30(2):197-201.
105. Stohl W., Scholz J.L., Cancro M.P. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr. Opin. Rheumatol. 2011, 23(3):305-310.